{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113883.3.3616.200.110.102.4026",
  "meta" : {
    "versionId" : "5",
    "lastUpdated" : "2022-07-14T01:03:32.000-04:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "Clinical Architecture"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2023-06-21"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2022-07-14"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.4026",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113883.3.3616.200.110.102.4026"
    }
  ],
  "version" : "20220714",
  "name" : "AdministrationOfBamlanivimab",
  "title" : "Administration of Bamlanivimab",
  "status" : "active",
  "experimental" : false,
  "date" : "2023-06-21T18:16:37-04:00",
  "publisher" : "Clinical Architecture",
  "jurisdiction" : [
    {
      "extension" : [
        {
          "url" : "http://hl7.org/fhir/StructureDefinition/data-absent-reason",
          "valueString" : "UNKNOWN"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: This set of values contains terms related to administration of bamlanivimab.),(Data Element Scope: ),(Inclusion Criteria: Includes introduction of bamlanivimab into central or peripheral veins via open or percutaneous routes.),(Exclusion Criteria: Excludes administration of other monoclonal antibodies (e.g., abciximab, infliximab) and routes of administration that do not involve open or percutaneous procedures (i.e. oral administration).)",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "concept" : [
          {
            "code" : "XW033F6",
            "display" : "Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6"
          },
          {
            "code" : "XW043F6",
            "display" : "Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:0ddb55cd-21e9-479e-a7f5-b276dac10cbd",
    "timestamp" : "2023-06-29T15:32:24-04:00",
    "total" : 2,
    "offset" : 0,
    "parameter" : [
      {
        "name" : "count",
        "valueInteger" : 1000
      },
      {
        "name" : "offset",
        "valueInteger" : 0
      }
    ],
    "contains" : [
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "XW033F6",
        "display" : "Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "XW043F6",
        "display" : "Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6"
      }
    ]
  }
}
